Ionis Pharmaceuticals has secured FDA approval for Zanvastro, marking a landmark moment as the first disease-modifying therapy ever cleared for Alexander disease.
The approval arrived more than two weeks ahead of its September 22 PDUFA date, signalling strong regulatory confidence in the drug’s clinical profile.
Alexander disease is an ultra-rare, progressive and often fatal neurological disorder that can affect motor, cognitive, autonomic and gastrointestinal function in both children and adults.
Until now, treatment options for the condition had been limited almost entirely to managing symptoms, leaving patients without any therapy targeting the underlying disease mechanism.
Zanvastro, formerly known as zilganersen, directly targets the protein buildup that drives Alexander disease, representing an entirely new approach to treating the condition.
The FDA granted approval for use across both paediatric and adult patient populations, following results from a pivotal clinical trial that demonstrated meaningful clinical benefit.
In that trial, walking speed remained stable among treated patients, while those in the control group experienced a 33% decline, a result that underscored the drug’s impact on disease progression.
Ionis (IONS) estimates that Zanvastro could generate peak sales of more than $100 million, though the company acknowledges that reaching that threshold may take time given the need to identify patients and establish treatment access.
The rare nature of Alexander disease means building awareness among clinicians and creating pathways for patient identification will be critical commercial priorities for Ionis in the months ahead.
Outside the United States, commercial partner Recordati is expected to file for regulatory approval in both the European Union and Japan next year, broadening the drug’s potential global reach.
Ionis also received a Rare Pediatric Disease Priority Review Voucher alongside the approval, an asset that carries significant market value if sold to another pharmaceutical company.
The company has not yet determined whether it will deploy the voucher for an internal programme or sell it on the open market, leaving that decision open for a later stage.
The approval is strategically significant for Ionis (IONS) beyond Zanvastro itself, establishing a foundational pillar for the company’s ambition to build an independent neurology franchise without relying on a larger commercial partner in the United States.